GSK said it will use its established manufacturing network in Belgium to support production. The companies will also work together to research, develop and manufacture several mRNA vaccine ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

GSK has made another investment in its manufacturing ... unveiled plans to build a $270 million-plus vaccines facility in Belgium. Neurotech Pharma's cell therapy Encelto has become the first ...

GSK said it will maintain space in Rockville ... it also has R&D sites in San Francisco and Boston in the U.S. as well as in Belgium, Italy and Spain. The company also inherited the Belward ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...